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Introduction: Double-unit umbilical cord blood trans-
plantation (dCBT) is a validated strategy to broaden access to
hematopoietic stem cell transplantation (HSCT), but is
limited by delayed engraftment and immune reconstitution.
ATG is a part of conventional myeloablative (MA) condi-
tioning for CBT, and although it may facilitate engraftment, it
can also contribute to delayed immune reconstitution
through T-cell depletion. We conducted a Phase II trial to
assess the safety and efﬁcacy of dCBT following a preparative
regimen combining total lymphoid irradiation (TLI, 400 cGy)
in lieu of ATG, with Fludarabine/Busulfan 3.2mg/kg IV x4
(FluBu4). Tacrolimus and mycophenolate mofetil were used
as GVHD prophylaxis.
Methods and Results: Twenty consecutive patients with
hematological malignant or non-malignant disorders were
enrolled between 2008 and 2012 at the University of Mich-
igan Blood and Marrow Transplantation Program. Trans-
plants consisted of two umbilical cord blood (UCB) units that
were at least a 4/6 HLA match to the pt, and 3/6 match to
each other. Median age was 49 yrs (range, 13-64 yrs). Most
patients had AML in CR1 or CR2 (40%), followed by NHL in PR
or better (25%), MDS (20%), ALL in early relapse (5%), MM in
VGPR (5%), and aplastic anemia (5%). Median HCT-CI pre-
transplant was 3 (0-7). Median total cells infused were
5.3x10
ˇ
7 (4-15.6x10
ˇ
7) of recipient body wt. Neutrophil
engraftment occurred in 85% of pts (95% CI, 60-95%), at a
median of 16 days (12-31), and 14/17 patients engrafted
within 26 days. Platelet engraftment occurred in 65% of pts
(95% CI, 40-82%) at a median of 43 days (26-86). Cumulative
incidences of grade II-IV and grade III/IV acute GVHD was
35% and 10%, respectively, and cumulative incidence of
chronic GVHD at 1 year was 25%. Relapse was the primary
cause of death and occurred in 6 pts (30%), all within 1 yr. At
days 100 and 365, cumulative incidence of TRM was 25%
(95% CI, 9-45%) and 35% (95% CI, 16-55%) respectively.
Transplant-related mortality trended to pts >50 yrs
(p¼0.058). The cause of TRM was GVHD in 5 patients and
graft failure in 2 patients. Two GVHD deaths resulted from
HSV-2 or HHV6 viremia while receiving high dose steroids.
OS at 1 year was 40% (95% CI, 19-60%), and 7 (35%) are in CR
after median follow up of 2.35 years post-transplant.
Conclusion: In summary, dCBT after MA conditioning with
FluBu4/TLI provides high engraftment rates with early
neutrophil recovery. Although conclusions regarding sur-
vival are limited due to sample size, this seemed to be in line
with previous reports, and was clearly better for younger
patients (<50 years old).321
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Introduction: HSCT is the only potentially curative therapy
for a well-selected group of patients with MDS. The objective
of this work was to describe a single center experience over
the past 15 years with HSCT in MDS patients.
Materials and Methods: Retrospective descriptive.
Patients: From 1997 to May 2013, 19 transplants have been
performed in 18 patients. 11 were male; mean age was 45
years (range 31-62).
11 patients had marrow failure as predominantly clinical
presentation; only one of these patients had not hadmultiple
transfusions at the time of transplantation. 5 patients were in
ﬁrst complete remission after induction chemotherapy. Only
3 patients received hypomethylating therapy before trans-
plantation. Median time from diagnosis to transplant was
296 days (range 58-950).
Results: PBSC fromHLA identical sibling donors where use in
18 transplants. One patient received PBSC from an HLA
identical URD. Conditioning treatment consisted on Fludar-
abine-PO Busulfán (11) or PO Busulfan-Cyclosphosphamide
(4) in the majority of patients. GVHD prophylaxis was per-
formed with Cyclosporine-MMF(10) or Cyclosporine-MTX
(5) in most cases.
17 patients engrafted; one patient had a primary graft
failure, which was rescued with a second transplant from the
same donor that also failed.
Mean CD34+ infused were 3.5 (range 1.05-4.64), mean
neutrophil graft was on day +12 (range 10-16), 4 patients (22
%) died before day 100 (graft failure, alveolar hemorrhage,
relapse, liver failure). 3 patients died after the 100th day, all
in relation to GVHD. With a median follow up of 24.1 months
(range: 0.7-89.1), overall survival was 61 %. GVHD was the
most frequent cause of death. 5 of the 7 deaths occurred in
the ﬁrst year.
Conclusion: The HSCT is a curative strategy for a signiﬁcant
percentage of patients with MDS.322
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plantation (HSCT) is an increasingly common treatment for
malignant and non-malignant hematologic diseases. The
major limitation to the realization of this type of transplant is
access to an HLA-identical donor within the family. Only 30%
of patients referred for transplantation will have an appro-
priate RD; using HLA-identical URD is an alternative for these
patients. The aim of this study is to describe the ﬁrst expe-
rience in Colombia with this type of transplant.
Materials and Methods: Observational case series.
Results: From July 1, 2011, have been 89 searches have been
started. The most frequent diagnosis acute leukemia (47 ALL,
25 AML). Since there isn’t a national donors registry, searches
were performed through NMDP. 26 matched-URD (10/10 or
9/10) were found (29.81%) and 14 transplants have been
performed. 8 patients with an URD died before trans-
plantation, 2 lost indication and 2 transplants are waiting.
The median time from the start of the search to ﬁnding
the donor was 52 days (range 28-240) and once the donor
was located it took a median of 67 days (range 36-94) to the
infusion.
Transplanted patients were 7 males/7 females, mean age
30 years (2-59), 9 had AML, 3 ALL and 2 SAA. Most leukemias
were in ﬁrst CR (10). Donors were on the majority young
(median 37 years; range 21-55), males (8), CMV positive.
PBSC were use in 10 cases.
Busulfan-Fludarabine-ATG conditioning regimen was
used for leukemia. GVHD prophylaxis consisted of Cs-MTX.
Survival: With a median follow up of 5.83 months (range:
0.86-17.9), 12 of the 14 patients are alive and in remission of
their disease (OS 85.7%). One patient died from aGVHD
complications and the other due to idiopathic pneumonitis. 2
of the 14 had grade III -IV aGVHD .
Conclusions: Allogeneic DNF is possible in Colombia and
results are the same that would be expected for a similar
population with RD. Low rates of success in ﬁnding an URD
for our Hispanic patients reﬂects the fact that they represent
a minority in world registries and highlight the need for the
creation of local registries.323
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Allo-SCT from an HLA related or unrelated donor is the ﬁrst
line treatment for newly diagnosed patients with BMFS
younger than 40 years, and for older patients that failed
immunosuppressive therapy.
Cohort retrospective analysis of BMFS patients receiving
Allo-SCT in a mixed (pediatric-adult) transplant center in
Bogota, Colombia, was performed to assess the inﬂuence of
different conditioning regimens in outcomes. Log-rank tests
(Lrt) analyses were used to determine the effects of age,
conditioning regimen and year of treatment on survival.Between January 1995 and August 2013, 96 transplants were
performed in 89 patients (70 acquired SAA, 16 Fanconi
Anemia, 2 pure red cell aplasia, 1 dyskeratosis congenita). 54
were males, mean age 25.8 years (range 4-60), mean time
from diagnosis to transplant 26.2 months (range 2.1-143),
60% were heavily transfused. Most donors were HLA iden-
tical siblings (81 PBSC, 7 BM); 3 transplants from unrelated
CBU, 2 from an haploidentical relative and 2 from an HLA
identical URD. Conditioning regimens used were: RIC Cy-Flu-
ATG (41), Cy-ATG (35) and Cy (14). 6 patients were condi-
tioned with Campath containing regimens and 2 with other.
Before 2004 most patients received Cs and MTX as GVHD
prophylaxis, after 2004 Cs and MMF was used in the
majority.
2 patients died due to sepsis before engraftment could be
evaluated. From the 87 evaluable patients, 5 had primary
graft failure and 4 secondary graft failure. 7/9 patients with
graft failure had a second transplant (5 from the same donor
and 2 from an haploidentical relative). 6 of those 7 trans-
plants engrafted and are alive. Non-myeloablative condi-
tioning containing Fludarabine, resulted in less hospital stay
compared to Cy-ATG and Cy alone (22.9, 32, 33 days
respectively), less fever (1.7, 6.7, 7 days), less parenteral
nutrition (0.1, 9, 4 days) and less red cells (2.4, 3.8, 3.8) and
platelet (4.5, 7.5, 9.75) transfusions. Rates of GII-IV aGVHD
were also less frequent for Cy-Flu-ATG group 8% compared to
Gy-ATG (18%) or Cy (25%). Extensive cGVHD was reported in
11%, 6% and 25% respectively.
The median follow-up was 23.06 months (range: 7.06-62.6).
Five-year overall survival (OS) was 69.23% for the entire
group. RIC-Flu-Cy-ATG resulted in signiﬁcantly better overall
survival (85.7%) compared to other regimens (66.6% for Cy-
ATG and 28.5% Cy (p¼0.0016). There was no signiﬁcant dif-
ference in survival related to age (p¼0.96). There as superior
survival for transplants performed after 2004 (n¼64)
compared with those before that year (n¼25) (80.3 vs 43.3%,
p¼0.004).
This single center experience suggest signiﬁcant overall
survival advantage of RIC-Flu-Cy-ATG over other condition-
ing regimens in high-risk BMFS patients regardless the age.
These results should be validated in prospective randomized
studies.324
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Acute and chronic GvHD occurs in 50-70% of patients un-
dergoing HCT despite GvHD prophylaxis. In this study, ECP
